Quince Therapeutics S.p.A.

Quick facts

Phase 3 pipeline

• EryDex High dose DSP · Immunology / Inflammatory disease
  EryDex High dose DSP is a dexamethasone formulation designed for enhanced delivery and bioavailability in treating inflammatory and immune-mediated conditions.
• EryDex Low dose DSP · Immunology
  EryDex Low dose DSP is a dexamethasone-based formulation designed to deliver corticosteroid therapy at reduced systemic doses while maintaining local therapeutic effect.

Phase 2 pipeline

• Dex 21-P · Rheumatology
  Dex 21-P is a glucocorticoid receptor antagonist.

Phase 1 pipeline

• DSP loaded RBC using EryDex System

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Quince Therapeutics S.p.A. portfolio CI brief
• Quince Therapeutics S.p.A. pipeline updates RSS